Evolution of ideas about pathological mineralization in soft tissues (literature review).

Authors

  • R. A. Moskalenko Sumy State University, Ukraine
  • A. M. Romanіuk Sumy State University, Ukraine

DOI:

https://doi.org/10.26641/1997-9665.2016.3.24-32

Keywords:

biomineralization, ectopic calcification, soft tissues, pathology

Abstract

Ectopic deposition of calcium compounds in the human body is represented by salts of calcium phosphate, mainly by hydroxyapatite. The formation of stones in the urinary system is the exception, there calcium oxalate and phosphate octacalcium are formed. As pathological biomineralization are presented by calcium compounds, the term "ectopic calcification" can be considered as identical or very similar in the meaning. Ectopic calcification is defined as unnatural mineralization of soft tissue of a living organism. Basing on the fact, that pathologic biomineralization is the result of cells and tissues damage, diseases, aging and systemic metabolic disorders, this process was viewed as degenerative and passive. This approach had dived pathological calcification into dystrophic and metastatic, and in native science also metabolic is marked out. Many recently opened specific regulatory calcification mechanisms of soft tissues indicate an activity of this process and its similarity to the processes of ossification of the skeletal system. A whole amount of new observations and researches convinces that the process of calcium compounds depositing in soft tissues are regulated and evolutionarily caused by compensatory and adaptive process. The concentration of calcium and phosphates in the extracellular fluid is close to that, which is necessary for the spontaneous formation of calcium phosphate crystals. Precipitation of minerals is prevented by inhibiting factors, the number of which is at enough basic level. Thus, ectopic biomineralization can be encouraged not only by activating factors increase, but also by an inhibitory factors decrease. Thus, various forms of pathological biomineralization can be caused by: 1) only activating factor increase 2) only decrease or loss of mineralization inhibitors, 3) a combination of violations of mineral formation activation and inhibition.

References

  1. Cotran RS, Kumare V, Robbins SL: Cellular injury and cellular death. Pathological basis of disease, 5th ed. Edited by SL Robbins. Philadelphia, WB Saunders; 1994. p. 1-35.
  2. Grynpas M. New insights into the mechanisms of biomineralization. Calcif Tissue Int. 2013; 93: 297-8.
  3. Vernadskiy VI. Biosfera [Biosphera]. I–II. Leningrad: Nauchtechn izdvo; 1926. 147 p. Russian.
  4. Srebnodolskiy BI. Biologicheskaia mineralogiia [Biological mineralogy]. Kyiv: Naukova dumka; 1983. 101 p. Russian.
  5. Zuzuk FB. Mineralogiia urolitiv [Mineralogy of uroliths]. I-III. Lutsk: Vezha; 2004. 582 p. Ukrainian.
  6. Giachelli CM. Inducers and inhibitors of biomineralization: lessons from pathological calcification. Orthod Craniofac Res. 2005; 8 (4):229-31.
  7. Block GA, Hulbert-Shearon TE. Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998; 31: 607-17.
  8. Strukov AI, Serov VV, Sarkissov DS. editors. [General human pathology] Moscow: Меditsina; 1990. 447 p. Russian.
  9. Anderson HC. Matrix vesicles and calcification. Curr Rheumatol Rep. 2003; 5(3):222-6.
  10. Moskalenko R, Rieznik A, Gapchenko A, et al. [Morphological examination of thyroid diseases accompanied by biomineralization]. World of medicine and biology. 2015; (3): 324-31. Ukrainian.
  11. Tang Z, Wang A, Yuan F et al. Differentiation of multipotent vascular stem cells contributes to vascular diseases. Nat Commun. 2012; 3: 875.
  12. Schiller A.L, Teitelbaum S.L. Bones and joints. In: Rubin E.; Farber JL, editors. Pathology. Lippincott-Raven; 1999. P. 1337-47.
  13. Proudfoot D, Skepper JN, Hegyi L, et al. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ Res. 2000; 87: 1055-62.
  14. Sage AP, Tintut Y, Demer LL. Hyperphosphatemia-induced nanocrystal upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int. 2011; 74: 414-22.
  15. Demer LL, Tintut Y. Inflammatory, metabolic, and genetic mechanisms of vascular calcification. Arterioscler Thromb Vasc Biol. 2014; 34 (4): 715-23.
  16. Anderson HC, Garimella R, Tague SE. The role of matrix vesicles in growth plate development and biominerals. Front Biosci. 2005; 10:822-37.
  17. Kirsch T. Determinants of pathological mineralization. Crit Rev Eukaryot Gene Expr. 2008; 18 (1):1-9.
  18. Anderson HC. Mineralization by matrix vesicles. Scan Electron Microsc. 1984; (Pt 2):953-64.
  19. Kapustin AN, Davies JD, Reynolds JL, et al. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ Res. 2011; 109:e1-12.
  20. Chen NX, O’Neill KD, Chen X, Moe SM. Annexin-mediated matrix vesicle calcification in vascular smooth muscle cells. J Bone Miner Res. 2008; 23: 1798-805.
  21. New SE, Alikawa E. The role of extracellular vesicles in de novo mineralization: an additional novel mechanism of cardiovascular calcification. Arterioscler Thromb Vasc Biol. 2013; 33 (8): 1753-8.
  22. New SE, Goettsch C, Aikawa M, et al. Macrophage-derived matrix vesicles: an alternative novel mechanism for microcalcification in atherosclerotic plagues. Circ Res. 2013; 113: 72-7.
  23. Hessle L, Johnson KA, Anderson HC, et al. Tissue-nonspecific alkiline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulations of bone mineralization. PNAS. 2002 ; 99 : 9445-9.
  24. Yadav MC, Simao AM, Narisawa S, et al. Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function. J Bone Miner Res. 2011; 26: 286-97.
  25. Kiffer-Moreira T, Yadav MC, Zhu D, et al. Pharmacological inhibition of PHOSPHO1 suppresses smooth muscle cell calcification. J Bone Miner Res. 2013; 28: 81-91.
  26. Ueland T, Dahl CP, Gullestad L, et al. Circulating levels of non-phosphorylated undercarboxylated matrix Gla protein are associated with disease severity in patients with chronic heart failure. Cli Sci (Lond). 2011; 121: 119-27.
  27. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix Gla protein. Nature. 1997; 386: 78-81.
  28. Schurgers LJ, Teunissen KJ, Knapen MH, et al. Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: Undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol. 2005; 25: 1629-33.
  29. Furie B, Bouchard BA, Furie BC. Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid. Blood. 1999; 93 (6): 1798-808.
  30. Jahnen-Dechent W, Shafer C, Heiss A, Grotzinger J. Systemic inhibition of spontaneous calcification by the serum protein alpha 2-HS glycoprotein/fetuin. Z Kardiol. 2001; 90 (Suppl 3): 47-56.
  31. Jahnen W, Shafer C, Ketteler M, McKee MD. Mineral shaperones: a role for fetuin-A and osteopontin in the inhibition and regression of pathologic calcification. J Mol Med. 2008; 86: 379-89.
  32. Heiss A, Eckert T, Aretz A, Richtering W, van Dorp W, et al. Hierarchical role of fetuin A and acidic serum proteins in the formation and stabilization of calcium phosphate particles. J Biol Chem. 2008; 283: 14815-25.
  33. Gorski JP. Biomineralization of bone: a fresh view of the roles of non-collagenous proteins. Front Biosci. 2015; 16: 2598-621.
  34. Simonet WS, Lacey D, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89 (2): 309-19.
  35. Maziere C, Salle V, Gomilla C, Maziere JC. Oxidized low density lipoprotein enhanced RANKL expression in human osteoblast-like cells. Involvement of ERK, NfkappaB and NFAT. Biochim Biophys Acta. 2013 ; 1832 : 1756-64.
  36. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, et al. Osteoprotegerin-deficient mice develop early oncet osteoporosis and arterial calcification. Genes Dev. 1998 ; 12 : 1260-8.
  37. Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr (-/-) mice. Circulation. 2008 ; 117 : 411-20.
  38. Zhou S, Fang X, Xin H, Li W, Qui H, Guan S. Osteoprotegerin inhibits calcification of vascular smooth muscle cells via downregulation of the Notch1-RBP-Jkappa/Msx2 signaling pathway. PloS One. 2013 ; 8 :e68987.
  39. Schoppet M, Al-Fakhri N, Franke FE, et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg’s sclerosis and atherosclerosis. J Clin Endocrinol Metab. 2004; 89: 4104-12.
  40. Callegari A, Coons M, Ricks JL, Yang HL, Gross TS, et al. Bone marrow- or vessel wall-derived osteoprotegerin is sufficied to reduce atherosclerotic lesion size and vascular calcification. Athroscler Thromb Vasc Biol. 2013 ; 33 : 2491-500. doi: 10.1161/ATVBAHA.113.301755.
  41. Kuro-o M. Klotho as a regulator of oxidative stress and senescence. Biol Chem. 2008; 389: 233-41.
  42. Krajisnik T, Bjorklund P, Marsell R, et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. 2007; 195: 125-31.
  43. Hu MC, Shi M, Zhang J, Quinones H, Griffith C, Kuro-o M, Moe OW. Klotto dificiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2011 ; 22 : 124-36.
  44. Towler DA. Inorganic pyrophosphate: A paracrine regulator of vascular calcification and smooth muscle phenotype. Arterioscler Thromb Vasc Biol. 2005; 25: 651-4.
  45. Menini S, Iacobini C, Ricci C, et al. The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis. Cardiovasc Res. 2013; 100: 472-80.
  46. Nguyen N, Naik V, Speer MY. Diabetes mellitus accelerates cartilaginous metaplasia and calcification in atherosclerotic vessels of LDRr mutant mice. Cardiovasc Pathol. 2013; 22: 167-75.
  47. McCormick M, Rahimi F, Bobryshev YV, Gaus K, et al. S100A8 and S100A9 in human arterial wall. The journal of biological chemistry. 2005;280(50):41521-9.
  48. Hofman Bowman MA, Gawdzik J, Buchari U, Husain AN, Toth PT, Earley J, McNally EM. S100A12 in vascular smooth musle accelerates vascular calcification in apolipoprotein E-null mice by activating an osteogenic genes regulators program. Altherioscler Thromb Vasc Bio. 2011; 31: 337-44.
  49. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanism to clinical implications. Atherosclerosis. 2008; 196: 9-21.
  50. Zhu W, Sano H, Nagai R, et al. The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins. Biochem Biophys Res Commun. 2001; 280: 1183-8.
  51. Iacobini C, Menini S, Ricci C, et al. Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms. Arterioscl Thromb Vasc Bi-ol. 2009; 29: 831-6.
  52. Stock M, Schafer H, Stricker S, et al. Expression of galectin-3 in skeletal tissues is controlled by Runx2. J Biol Chem. 2003; 17360-7.
  53. Li Q, Jiang Q, Uitto J. Ectopic mineralization disorders of the extracellular matrix of connective tissue: molecular genetics and pathomechanisms of aberrant calcification. Matrix Biol. 2014 Jan;33:23-8. doi: 10.1016/j.matbio.2013.06.003.
  54. Pugliese G, Iacobini C, Blasetti-Fantanaucci C, Menini S. The dark and bright side of atherosclerotic calcification. Atherosclerosis. 2015; 238 (2):220-3.
  55. Hoshino T, Chow LA, Hsu JJ, et al. Mechanical stress analysis of a rigid inclusion in distensible material: a model of atherosclerotic calcification and plague vulnerability. Am J Physiol Heart Circ Physiol. 2009; 297: H802-10.
  56. Kelly-Arnold A, Maldonado N, Laudier D, et al. Revised microcalcification hypothesis for fibrous cap rupture in human coronary arteries, PNAS. 2013; 110: 10741-6.
  57. Liu Y, Drozdov I, Shroff R, Beltran LE, Shanaban CM. Prelamin A accelerates vascular calcification via activation of the DNA damage response and senescence-associated secretory phenotype in a vascular smooth muscle cells. Circ Res. 2013; 112: e99-109.
  59. Aikawa E, Nahrendorf M, Figueiredo JL, et al. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation. 2007; 116: 2841-50.
  60. Abdelbaky A, Corsini E, Figueroa AL, et al. Focal arterial inflammation precedes subsequent calcification in the same location: a longitudinal FDG-PET/CT study. Circ Cardiovasc Imaging. 2013; 6: 747-54.
  61. Abedin M, Lim J, Tang TB, et al. N-3 fatty acids inhibit vascular calcification via the p38-mitogen-activated protein kinase and peroxisome proliferator-activated receptor gamma pathways. Circ Res. 2006; 98: 727-9.
  62. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res. 2004; 95: 560-7.

Downloads

How to Cite

Moskalenko, R. A., & Romanіuk A. M. (2016). Evolution of ideas about pathological mineralization in soft tissues (literature review). Морфологія / Morphologia / Morfologìâ, 10(3), 24–32. https://doi.org/10.26641/1997-9665.2016.3.24-32

Issue

Vol. 10 No. 3 (2016)

Section

Статті

License

Copyright (c) 2018 Morphologia

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

 The authors reserve the right to authorship of their work and transfer to the Journal the right to the first publication of this work under the terms of a license Creative commons Attribution 4.0 International (CC BY 4.0), which allows other people to freely distribute the published work with a mandatory reference to the authors of the original work and the first publication of the work in this journal.
        By submitting a manuscript to the editorial office of the Journal ‘Morphologia’ authors agree to transfer the rights to protect and use the manuscript (all supplemental materials, particularly protected objects such as photos, drawings, diagrams, tables, etc.), including the reproduction in the press and distribution via the Internet; translation of the manuscript into any language; export and import of journal copies with the Authors’ article in order to make it available for public. Authors convey the rights mentioned above to the editorial office without any temporal or territorial limitation all over the world. 
        The Authors guarantee that they have the exclusive rights to use the material transferred to editorial office. Editors are not responsible to third parties for contraventions of warranty given by the Authors. The considered rights are transferred to the editorial office since the moment when the current issue is signed for publishing. Reproduction of materials published in the Journal by other individuals and legal entities is possible only with the consent of Editorial office, with the obligatory indication of the full bibliographic reference of the primary publication. The Authors reserve the right to use the published material, its fragments and parts for teaching materials, oral presentations, dissertation thesis prepararion with obligatory bibliographic citation of the original paper. Electron copy of the published article, downloaded from official journal web-site in .pdf format may be put by authors on the official web-site of their institutions, any other official resources with open access.